CYSTIC FIBROSIS (CF) IS A LETHAL AUTOSOMAL RECESSIVE DISEASEAFFECTING MAINLY WHITE CHILDREN.

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
4881
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Healthgenics Inc
4202 Gardendale, Suite 102, San Antonio, TX, 28229
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 BETTY J DABNEY
 PRINCIPAL INVESTIGATOR
 (512) 690-9984
Business Contact
Phone: () -
Research Institution
N/A
Abstract
CYSTIC FIBROSIS (CF) IS A LETHAL AUTOSOMAL RECESSIVE DISEASEAFFECTING MAINLY WHITE CHILDREN. THE RISK OF BEING A CARRIER OF THE CYSTIC FIBROSIS GENE IN THE WHITE POPULATION IS HIGH-APPROXIMATELY 5%. AFFECTED INDIVIDUALS WITH CYSTIC FIBROSIS CAN BE DIAGNOSED BY HIGH SWEAT CHLORIDE LEVELS WITHAPPROXIMATELY 98% RELIABILITY. HOWEVER, THOSE INDIVIDUALS WHO CARRY A SINGLE CYSTIC FIBROSIS GENE AND ARE POTENTIAL PARENTS OF CYSTIC FIBROSIS CHILDREN CANNOT BE DIAGNOSED. FOR EXAMPLE, NORMAL SIBLINGS OF CYSTIC FIBROSIS PATIENTS HAVE A 66.6% CHANCE OF CARRYING ONE OF THE DEFECTIVE GENES LEADING TO CYSTIC FIBROSIS. SUCH INDIVIDUALS AND OTHERS AREINTERESTED IN A DIAGNOSTIC TEST FOR DETECTING THE CYSTIC FIBROSIS GENE. THE COMMERCIAL APPLICATION OF DNA TECHNOLOGYTOWARD DEVELOPING A COMMERCIAL TEST FOR THE CYSTIC FIBROSIS GENE WILL BE THE LONG-TERM OBJECTIVE OF THIS PROJECT. PHASEI OF THIS PROJECT WILL IDENTIFY ONE OR MORE DNA POLYMORPH- ISMS THAT COSEGREGATE WITH THE CYSTIC FIBROSIS GENE BACAUSE OF THEIR PROXIMITY TO THE GENE ON A HUMAN CHROMOSOME. IDENTIFICATION OF SUITABLE DMA POLYMORPHISMS WILL BE USED TOSTUDY THE FEASIBILITY OF DETECTING THE SEGREGATION OF THE CFGENE IN FAMILIES FROM TEXAS, NEW YORK, AND MEXICO.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government